Alzheimer's Clinical Trials Consortium | ClinicalTrials HQ

10 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
The Progressive Supranuclear Palsy Clinical Trial Platform	Neurologic Manifestations, Ocular Motility Disorders, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, basal ganglia disorder, brain disorder, central nervous system disorder, cranial nerve neuropathy, eye disorder, movement disorder, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, tauopathy	Recruiting	Phase 2	2026-10-09		NCT07173803
Alzheimer's Tau Platform: Regimen A - AADvac1	Alzheimer disease, Frontotemporal Lobar Degeneration, Pick disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, frontotemporal dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy	Enrolling by invitation	Phase 2	2026-09-08		NCT07167966
Alzheimer's Tau Platform: Master Protocol	Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Nerve Degeneration, Pathologic Processes, Pathological Conditions, Signs and Symptoms, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy	Recruiting	Phase 2	2026-09-08		NCT06957418
Alzheimer's Plasma Extension	Alzheimer disease, Cognition Disorders, Cognitive Dysfunction, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy	Enrolling by invitation	Not stated	2026-08-18		NCT06416072
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1	Frontotemporal Lobar Degeneration, Neurologic Manifestations, Nutritional and Metabolic Diseases, Ocular Motility Disorders, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, cranial nerve neuropathy, dementia, eye disorder, frontotemporal dementia, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, proteostasis deficiencies, psychiatric disorder, tauopathy	Enrolling by invitation	Phase 2	2026-08-13		NCT07217665
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31	Frontotemporal Lobar Degeneration, Neurologic Manifestations, Nutritional and Metabolic Diseases, Ocular Motility Disorders, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, TDP-43 proteinopathy, basal ganglia disorder, brain disorder, central nervous system disorder, cognitive disorder, cranial nerve neuropathy, dementia, eye disorder, frontotemporal dementia, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease, ophthalmoplegia, palsy, proteostasis deficiencies, psychiatric disorder, tauopathy	Enrolling by invitation	Phase 2	2026-08-12		NCT07264283
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease	Alzheimer disease, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy	Active, not recruiting	Phase 2	2026-08-10		NCT05531656
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid	Early Preclinical Alzheimer's Disease; Preclinical Alzheimer's Disease	Active, not recruiting	Phase 3	2026-06-04		NCT04468659
Trial-Ready Cohort-Down Syndrome (TRC-DS)	Abnormalities, Multiple, Alzheimer disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Down syndrome, Neurobehavioral Manifestations, Neurologic Manifestations, brain disorder, central nervous system disorder, chromosomal disorder, cognitive disorder, dementia, hereditary disease, intellectual disability, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy	Recruiting	Not stated	2026-05-18		NCT04165109
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation	Abnormalities, Multiple, Alzheimer disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Down syndrome, Neurobehavioral Manifestations, Neurologic Manifestations, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Plaque, Amyloid, brain disorder, central nervous system disorder, chromosomal disorder, cognitive disorder, dementia, hereditary disease, intellectual disability, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy	Not yet recruiting	Phase 4	2026-05-15		NCT06911944